Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Mequitazine→

Mequitazine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
29216-28-2
Molecular formula
C20H22N2S
Molecular weight
322.5 g/mol
Drug class
First-generation phenothiazine antihistaminehistamine H1 receptor antagonist
Mechanism of action
Antagonises peripheral histamine H1 receptors and reduces histamine-mediated allergic symptoms. It has sedative and anticholinergic properties; receptor selectivity and risk profile vary by dose and formulation.
Indications / reported uses
  • Symptomatic treatment of allergic rhinitis and urticaria in countries where mequitazine products are authorised; current availability and age restrictions are jurisdiction-specific

Sources: NLM MeSH — Mequitazine · PubMed — Mequitazine antihistamine pharmacology · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Mequitazine Environmental Risk Assessment (ERA) (the Mequitazine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.